During the past decade, Tokyo Metropolitan Ohtsuka Hospital conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Metropolitan Ohtsuka Hospital" #1 collaborator was "Regeneron Pharmaceuticals" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Metropolitan Ohtsuka Hospital" are "Retinopathy of Prematurity (ROP)" (2 trials) and "Type 2 Diabets Mellitus" (1 trials). Many other conditions were trialed in "Tokyo Metropolitan Ohtsuka Hospital" in a lesser frequency.

Most popular intervention types in "Tokyo Metropolitan Ohtsuka Hospital" are "Drug" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Eylea (Aflibercept, BAY86-5321)" (2 trials), "Laser photocoagulation" (2 trials) and "nateglinide(drug) mitiglinide(drug)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Metropolitan Ohtsuka Hospital" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Tokyo Metropolitan Ohtsuka Hospital". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Tokyo Metropolitan Ohtsuka Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Metropolitan Ohtsuka Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".